Discovery of multitarget inhibitors by combining molecular docking with common pharmacophore matching

Journal of Medicinal Chemistry

Volumn 51, Issue 24, 2008, Pages 7882-7888

  Wei, Dengguo ^a,b   Jiang, Xiaolu ^a   Zhou, Lu ^a   Chen, Jing ^a,b   Chen, Zheng ^a   He, Chong ^a   Yang, Kun ^a,b   Liu, Ying ^a   Pei, Jianfeng ^b   Lai, Luhua ^a,b  

^a PEKING UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

[3 (1 BENZYL 3 CARBAMOYLMETHYL 2 METHYL 1H INDOL 5 YLOXY)PROPYL]PHOSPHONIC ACID; ARACHIDONIC ACID; BESTATIN; ENZYME INHIBITOR; INDOLE; LEUKOTRIENE A4 HYDROLASE; SECRETORY PHOSPHOLIPASE A2; UNCLASSIFIED DRUG;

ARACHIDONIC ACID METABOLISM; ARTICLE; COMBINATORIAL LIBRARY; COMPUTER ANALYSIS; DATA BASE; ENZYME ACTIVITY; ENZYME INHIBITION; HYDROPHOBICITY; IC 50; LIGAND BINDING; MATHEMATICAL MODEL; MOLECULAR DOCKING; PHARMACOPHORE;

BIOPHYSICAL PROCESSES; CHEMISTRY, PHARMACEUTICAL; COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPOXIDE HYDROLASES; HUMANS; INHIBITORY CONCENTRATION 50; KINETICS; MODELS, CHEMICAL; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE; PHOSPHOLIPASES A2; PROTEIN BINDING;

EID: 58149088865     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm8010096     Document Type: Article

References (37)

1. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discovery Today 2004, 9, 641-651.
2. Brown, D.; Superti-Furga, G. Rediscovering the sweet spot in drug discovery. Drug Discovery Today 2003, 8, 1067-1077.
3. Szuromi, P.; Vinson, V.; Marshall, E. Rethinking drug discovery. Introduction. Science 2004, 303, 1795.
4. Overington, J. P.; Al-Lazikani, B.; Hopkins, A. L. Opinion. How many drug targets are there? Nat. Rev. Drug Discovery 2006, 5, 993-996.
5. Csermely, P.; Agoston, V.; Pongor, S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol. Sci. 2005, 26, 178-182.
6. Huang, S. Rational drug discovery: what can we learn from regulatory networks. Drug Discovery Today 2002, 7, S163-S169.
7. Borisy, A. A.; Elliott, P. J.; Hurst, N. W.; Lee, M. S.; Lehar, J.; Price, E. R.; Serbedzija, G.; Zimmermann, G. R.; Foley, M. A.; Stockwell, B. R.; Keith, C. T. Systematic discovery of multicomponent therapeutics. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 7977-7982.
8. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. J. Med. Chem. 2005, 48, 6523-6543.
9. Morphy, R.; Rankovic, Z. Fragments, network biology and designing multiple ligands. Drug Discovery Today 2007, 12, 156-160.
10. Morphy, R. The influence of target family and functional activity on the physicochemical properties of pre-clinical compounds. J. Med. Chem. 2006, 49, 2969-2978.
11. Hopkins, A. L.; Mason, J. S.; Overington, J. P. Can we rationally design promiscuous drugs? Curr. Opin. Struct. Biol. 2006, 16, 127-136.
12. Yang, K.; Ma, W. Z.; Liang, H. H.; Qi, O. Y.; Tang, C.; Lai, L. H. Dynamic simulations on the arachidonic acid metabolic network. PLoS Comput. Biol. 2007, 3, 523-530.
13. Reid, R. C. Inhibitors of secretory phospholipase A2 group IIA. Curr. Med. Chem. 2005, 12, 3011-3026.
14. Penning, T. D. Inhibitors of leukotriene A(4) (LTA(4)) hydrolase as potential anti-inflammatory agents. Curr. Pharm. Des. 2001, 7, 163-179.
15. Chen, J.; Lai, L. H. Pocket v.2: further developments on receptor-based pharmacophore modeling. J. Chem. Inf. Model. 2006, 46, 2684-2691.
16. Thunnissen, M. M. G. M.; Nordlund, P.; Haeggstrom, J. Z. Crystal structure of human leukotriene A(4) hydrolase, a bifunctional enzyme in inflammation. Nat. Struct. Biol. 2001, 8, 131-135.
17. Schevitz, R. W.; Bach, N. J.; Carlson, D. G.; Chirgadze, N. Y.; Clawson, D. K.; Dillard, R. D.; Draheim, S. E.; Hartley, L. W.; Jones, N. D.; Mihelich, E. D.; Olkowski, J. L.; Snyder, D. W.; Sommers, C.; Wery, J. P. Structure-based design of the first potent and selective inhibitor of human nonpancreatic secretory phospholipase-A(2). Nat. Struct. Biol. 1995, 2, 458-465.
18. Haeggstrom, J. Z. Leukotriene A(4) (hydrolase/aminopeptidase, the gatekeeper of chemotactic leukotriene B)(4) biosynthesis. J. Biol. Chem. 2004, 279, 50639-50642.
19. Ollmann, I. R.; Heather Hogg, J.; Munoz, B.; Haeggstrom, J. Z.; Samuelsson, B.; Wong, C. H. Investigation of the inhibition of leukotriene A4 hydrolase. Bioorg. Med. Chem. 1995, 3, 969-995.
20. Huang, C. K.; Zhou, L.; Liu, Y.; Lai, L. G. A continuous fluorescence assay for phospholipase A(2) with nontagged lipid. Anal. Biochem. 2006, 351, 11-17.
21. Penning, T. D.; Chandrakumar, N. S.; Chen, B. B.; Chen, H. Y.; Desai, B. N.; Djuric, S. W.; Docter, S. H.; Gasiecki, A. F.; Haack, R. A.; Miyashiro, J. M.; Russell, M. A.; Yu, S. S.; Corley, D. G.; Durley, R. C.; Kilpatrick, B. F.; Parnas, B. L.; Askonas, L. J.; Gierse, J. K.; Harding, E. I.; Highkin, M. K.; Kachur, J. F.; Kim, S. H.; Krivi, G. G.; Villani-Price, D.; Pyla, E. Y.; Smith, W. G.; Ghoreishi-Haack, N. S. Structure-activity relationship studies on 1-[2-(4-phenylphenoxy)ethyl] pyrrolidine (SC-22716), a potent inhibitor of leukotriene A(4) (LTA(4)) hydrolase. J. Med. Chem. 2000, 43, 721-735.
22. Zambrowicz, B. P.; Sands, A. T. Knockouts model the 100 best-selling drugs. Will they model the next 100? Nat. Rev. Drug Discovery 2003, 2, 38-51.
23. Wagner, A. Robustness against mutations in genetic networks of yeast. Nat. Genet. 2000, 24, 355-361.
24. Korcsmáros, T.; Szalay, M. S.; Böde, C.; Kovács, I. A.; Csermely, P. How to design multi-target drugs: target search options in cellular networks. Expert Opin. Drug Discovery 2007, 2, 799-808.
25. Rogawski, M. A. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents - toward an understanding of their favorable tolerability. Amino Acids 2000, 19, 133-149.
26. Palmer, G. C.; Cregan, E. F.; Bialobok, P.; Sydserff, S. G.; Hudzik, T. J.; McCarthy, D. J. The low-affinity, use-dependent NMDA receptor antagonist AR-R 15896AR. An update of progress in stroke. Neuroprotective Agents: Fourth International Conference 1999, 890, 406-420.
27. Mueller, A. L.; Artman, L. D.; Balandrin, M. F.; Brady, E.; Chien, Y. W.; Delmar, E. G.; George, K.; Kierstead, A.; Marriott, T. B.; Moe, S. T.; Newman, M. K.; Raszkiewicz, J. L.; Sanguinetti, E. L.; Van Wagenen, B. C.; Wells, D. NPS 1506, a novel NMDA receptor antagonist and neuroprotectant - Review of preclinical and clinical studies. Neuroprot. Agents, Int. Conf., 4th 1999, 890, 450-457.
28. Lipton, S. A. Turning down, but not off. Nature 2004, 428, 473.
29. Thunnissen, M. M. G. M.; Andersson, B.; Samuelsson, B.; Wong, C. H.; Haeggstrom, J. Z. Crystal structures of leukotriene A(4) hydrolase in complex with captopril and two competitive tight-binding inhibitors. FASEB J. 2002, 16, 1648-1650.
30. Kirkland, T. A.; Adler, M.; Bauman, J. G.; Chen, M.; Haeggstrom, J. Z.; King, B.; Kochanny, M. J.; Liang, A. M.; Mendoza, L.; Phillips, G. B.; Thunnissen, M.; Trinh, L.; Whitlow, M.; Ye, B.; Ye, H.; Parkinson, J.; Guilford, W. J. Synthesis of glutamic acid analogs as potent inhibitors of leukotriene A(4) hydrolase. Bioorg. Med. Chem. 2008, 16, 496-4983.
31. Penning, T. D.; Chandrakumar, N. S.; Desai, B. N.; Djuric, S. W.; Gasiecki, A. F.; Malecha, J. W.; Miyashiro, J. M.; Russell, M. A.; Askonas, L. J.; Gierse, J. K.; Harding, E. I.; Highkin, M. K.; Kachur, J. F.; Kim, S. H.; Villani-Price, D.; Pyla, E. Y.; Ghoreishi-Haack, N. S.; Smith, W. G. Synthesis of imidazopyridines and purines as potent inhibitors of leukotriene A(4) hydrolase. Bioorg. Med. Chem. Lett. 2003, 13, 1137-1139.
32. Penning, T. D.; Chandrakumar, N. S.; Chen, B. B.; Chen, H. Y.; Desai, B. N.; Djuric, S. W.; Docter, S. H.; Gasiecki, A. F.; Haack, R. A.; Miyashiro, J. M.; Russell, M. A.; Yu, S. S.; Corley, D. G.; Durley, R. C.; Kilpatrick, B. F.; Parnas, B. L.; Askonas, L. J.; Gierse, J. K.; Harding, E. I.; Highkin, M. K.; Kachur, J. F.; Kim, S. H.; Krivi, G. G.; Villani-Price, D.; Pyla, E. Y.; Smith, W. G.; Ghoreishi-Haack, N. S. Structure-activity relationship studies on 1-[2-(4-phenylphenoxy)ethyl] pyrrolidine (SC-22716), a potent inhibitor of leukotriene A(4) (LTA(4)) hydrolase. J. Med. Chem. 2000, 43, 721-735.
33. Wei, Y. A.; Munoz, B.; Wong, C. H.; Haeggstrom, J. Z.; Wetterholm, A.; Samuelsson, B. Development of selective tight-binding inhibitors of leukotriene-A4 hydrolase. J. Med. Chem. 1993, 36, 211-220.
34. Hogg, J. H.; Ollmann, I. R.; Haeggstrom, J. Z.; Wetterholm, A.; Samuelsson, B.; Wong, C. H. Amino hydroxamic acids as potent inhibitors of leukotriene A(4) hydrolase. Bioorg. Med. Chem. 1995, 3, 1405-1415.
35. Penning, T. D.; Askonas, L. J.; Djuric, S. W.; Haack, R. A.; Yu, S. S.; Michener, M. L.; Krivi, G. G.; Pyla, E. Y. Kelatorphan and related analogs. Potent and selective inhibitors of leukotriene A(4) hydrolase. Bioorg. Med. Chem. Lett. 1995, 5, 2517-2522.
36. Penning, T. D.; Chandrakumar, N. S.; Desai, B. N.; Djuric, S. W.; Gasiecki, A. F.; Liang, C. D.; Miyashiro, J. M.; Russell, M. A.; Askonas, L. J.; Gierse, J. K.; Harding, E. I.; Highkin, M. K.; Kachur, J. F.; Kim, S. H.; Villani-Price, D.; Pyla, E. Y.; Ghoreishi-Haack, N. S.; Smith, W. G. Pyrrolidine and piperidine analogues of SC-57461A as potent, orally active inhibitors of leukotriene A(4) hydrolase. Bioorg. Med. Chem. Lett. 2002, 12, 3383-3386.
37. Ewing, T. J. A.; Makino, S.; Skillman, A. G.; Kuntz, I. D. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J. Comput.-Aided Mol. Des. 2001, 15, 411-428.